BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/17/2025 6:18:58 AM | Browse: 83 | Download: 16
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Anwei decoction alleviates chronic atrophic gastritis by modulating the gut microbiota-metabolite axis and NLRP3 inflammasome activity
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong Qin, Yi-Yang Liu, Qiang Li, Sai-Yan Wei, Li-Yun Huang, Chai-Feng Zhou, Li-Yan Tan, Jing-Wen Zhang, De-Kun Wu and You-Ming Tang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 81860843 |
| Guangxi Administration of Traditional Chinese Medicine Project |
No. GZSY23-36 |
| Guangxi Administration of Traditional Chinese Medicine Project |
No. GXZYA20240150 |
|
| Corresponding Author |
De-Kun Wu, Associate Professor, Professor, Teaching Experiment and Training Center, Guangxi University of Chinese Medicine, No. 179 East Mingxiu Road, Xixiangtang District, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 1278323777@qq.com |
| Key Words |
Anwei decoction; Chronic atrophic gastritis; Gut microbiota-metabolite axis; NLRP3 inflammasome; Traditional Chinese medicine |
| Core Tip |
Chronic atrophic gastritis (CAG) is a precancerous lesion of the stomach, with a prevalence of 34.7% in China and a risk of gastric cancer that is 4 times that of ordinary people. Existing therapies have high side effects and cannot reverse pathological damage. Traditional Chinese medicine Anwei decoction inhibits NLRP3 inflammasomes, reshapes the balance of microflora, breaks through the limitations of single targets, and provides a new strategy for CAG treatment, which can delay cancer and reverse pathological damage through the regulation of the “microbiota-metabolism-immunity” network. |
| Citation |
Qin H, Liu YY, Li Q, Wei SY, Huang LY, Zhou CF, Tan LY, Zhang JW, Wu DK, Tang YM. Anwei decoction alleviates chronic atrophic gastritis by modulating the gut microbiota-metabolite axis and NLRP3 inflammasome activity. World J Gastroenterol 2025; In press |
 |
Received |
|
2025-08-25 06:05 |
 |
Peer-Review Started |
|
2025-08-25 06:06 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-09-22 09:37 |
 |
Revised |
|
2025-10-03 17:34 |
 |
Second Decision |
|
2025-11-17 02:37 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-11-17 06:18 |
 |
Articles in Press |
|
2025-11-17 06:18 |
 |
Publication Fee Transferred |
|
2025-10-07 13:58 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345